John Wiprud, MD
Family Medicine · Heath, TXNPI 1457373714
Payments from drug & device makers
Across 478 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$612
- GSK$594
- Pfizer$547
- AbbVie$504
- Sanofi-aventis U.S. LLC$497
- plus $4K from 32 others
What the payments were for
- Food & beverage$7,950100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 80 | $1,311 |
| AstraZeneca | 33 | $612 |
| GSK | 40 | $594 |
| Pfizer | 37 | $547 |
| AbbVie | 33 | $504 |
| Sanofi-aventis U.S. LLC | 35 | $497 |
| Abbott | 24 | $464 |
| Astellas Pharma US Inc | 22 | $458 |
| Merck | 32 | $408 |
| Lilly USA, LLC | 25 | $373 |
| Dexcom, Inc. | 10 | $269 |
| Bayer | 13 | $251 |
| Idorsia Pharmaceuticals US Inc | 16 | $236 |
| Antares Pharma, Inc. | 12 | $181 |
| Exact Sciences | 7 | $153 |
| Sumitomo Pharma America, Inc. | 6 | $138 |
| Amarin Pharma, Inc. | 6 | $116 |
| Phathom Pharmaceuticals, Inc. | 5 | $81 |
| Corcept Therapeutics | 2 | $74 |
| Sanofi Pasteur Inc. | 4 | $60 |
| Axsome Therapeutics, Inc. | 2 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Genentech USA, Inc. | 3 | $54 |
| Amgen | 3 | $51 |
| Amneal Pharmaceuticals LLC | 3 | $48 |
| Halozyme Inc | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Johnson & Johnson | 2 | $37 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Adlon Therapeutics L.p. | 2 | $32 |
| Shire North American Group Inc | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $20 |
| Organon | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| GE HealthCare | 1 | $13 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$124
- BREZTRI$124
- FARXIGA$124
- DEXCOM G6 TRANSMITTER$114
How this compares
$7,950 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $136,735 |
| JardianceEmpagliflozin | 51 | $69,429 |
| FarxigaDapagliflozin Propanediol | 38 | $50,163 |
| MounjaroTirzepatide | 28 | $37,924 |
| JanuviaSitagliptin Phosphate | 29 | $36,731 |
| EliquisApixaban | 30 | $36,541 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $28,036 |
| XareltoRivaroxaban | 13 | $19,177 |
| SynthroidLevothyroxine Sodium | 39 | $4,638 |
| Gabapentin | 118 | $3,099 |
| Levothyroxine Sodium | 271 | $3,043 |
| Metoprolol Succinate | 187 | $2,972 |
| Atorvastatin Calcium | 287 | $2,944 |
| Omeprazole | 192 | $2,801 |
| Losartan Potassium | 235 | $2,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,311 | $136,735131 claims |
| AstraZenecaFarxiga | $612 | $50,16338 claims |
| Lilly USA, LLCMounjaro | $373 | $37,92428 claims |
| MerckJanuvia | $408 | $36,73129 claims |
| PfizerEliquis | $547 | $36,54130 claims |
| GSKTrelegy Ellipta | $594 | $28,03632 claims |
| Johnson & JohnsonXarelto | $37 | $19,17713 claims |
| AbbVieSynthroid | $504 | $4,63839 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $48 | $3,043271 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Heath
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.